GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients
18 Aug 2025
byJairia Dela Cruz
New research suggests that in older adults with type 2 diabetes (T2D) who are taking metformin, using dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) has a null effect on the risk of COVID-19 infection. However, among those who do contract the virus, the use of these drugs appears to lower the risk of hospitalization.
GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients
18 Aug 2025
